Clinical Trial Update: Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and efficacy of universal CD19 CAR-T cells (UWD-CD19) with immunosuppressants for refractory autoimmune diseases; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Inflammatory Myopathies
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• UWD-CD19 Universal CAR-T Cells (universal CD19-targeted CAR-T cells)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING